Drug Profile

EX 105

Alternative Names: EX-105

Latest Information Update: 29 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Guangzhou Excelmab
Class Antineoplastics; Bispecific antibodies; Immunotherapies
Mechanism of Action Antibody-dependent cell cytotoxicity; CD276 protein inhibitors; CD3 antigen inhibitors; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

31 May 2024 Preclinical trials in Solid tumours in China (Parenteral) before May 2024
31 May 2024 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 60^th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
31 May 2024 Guangzhou ExcelMab plans a first-in-human clinical trial in Solid tumours is due to start

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com